cme.medlearning.de - CME Logo

Literatur

  1. Rau JL. The inhalation of drugs: advantages and problems. Respir Care 2005; 50:367-382.
  2. Gandevia B. Historical review of the use of parasympatholytic agents in the treatment of respiratory disorders. Postgrad Med J 1975; 51:13-20.
  3. Berdel D, Buhl R, Dierkesmann R, et al. Nationale Versorgungs-Leitlinie Asthma, 2005.
  4. National Institutes of Health, National Heart LaBI. Expert Panel Report II. Guidelines for the diagnosis and management of asthma. In. Bethesda, 1997.
  5. Global Initiative for Chronic Obstructive Lung Disease (GOLD), World Health Organization (WHO), National Heart LaBIN. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Bethesda (MD): Global Initiative for Chronic Obstructive Lung Disease. Bethesda, 2005.
  6. Neue Wege in der Inhalationstherapie obstruktiver Atemwegserkrankungen. München: Dustri-Verlag Dr. Karl Feistle, 1990.
  7. Voshaar T. Therapie mit Aerosolen. Bremen: UNI-MED Verlag, 2004.
  8. Muers MF. Overview of nebuliser treatment. Thorax 1997; 52 Suppl 2:S25-30.
  9. Matthys H. Praxis der Aerosoltherapie. In: Scheuch G, ed. Aerosole in der Inhalationstherapie II. München: Dustri-Verlag Dr. Karl Feistle, 1998.
  10. Voshaar T, App EM, Berdel D, et al. Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung. Arbeitsgruppe Aerosolmedizin der Deutschen Gesellschaft für Pneumologie. Pneumologie 2001; 55:579-586.
  11. Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest 2005; 127:335-371.
  12. Freedman T. Medihaler therapy for bronchial asthma; a new type of aerosol therapy. Postgrad Med 1956; 20:667-673.
  13. Thiel GC. From Susie's question to CFC free: an inventor's perspective on forty years of MDI development and regulation. In: Dalby RN, Byron PR, Farr SJ, eds. Respiratory drugs delivery. Buffalo Grove: Interpharm Press, 1996; 115-123.
  14. Newman SP, Moren F, Pavia D, Little F, Clarke SW. Deposition of pressurized suspension aerosols inhaled through extension devices. Am Rev Respir Dis 1981; 124:317-320.
  15. Dolovich M, Ruffin R, Corr D, Newhouse MT. Clinical evaluation of a simple demand inhalation MDI aerosol delivery device. Chest 1983; 84:36-41.
  16. Bell JH, Hartley PS, Cox JS. Dry powder aerosols. I. A new powder inhalation device. J Pharm Sci 1971; 60:1559-1564.
  17. Voshaar T, Hausen T, Kardos P, et al. Inhalationstherapie mit dem Respimat® Soft Inhaler bei Asthma und COPD. Pneumologie 2005; 59:25-32.
  18. Newman SP, Brown J, Steed KP, Reader SJ, Kladders H. Lung deposition of fenoterol and flunisolide delivered using a novel device for inhaled medicines: comparison of RESPIMAT with conventional metered-dose inhalers with and without spacer devices. Chest 1998; 113:957-963.
  19. Brocklebank D, Wright J, Cates C. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering corticosteroids in asthma. Bmj 2001; 323:896-900.
  20. Ram FS, Brocklebank DM, Muers M, Wright J, Jones PW. Pressurised metered-dose inhalers versus all other hand-held inhalers devices to deliver bronchodilators for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002:CD002170.
  21. Ram FS, Wright J, Brocklebank D, White JE. Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma. Bmj 2001; 323:901-905.
  22. Rau JL. Determinants of patient adherence to an aerosol regimen. Respir Care 2005; 50:1346-1356; discussion 1357-1349.
  23. Petro W, Gebert P, Lauber B. Ursachenanalysen fehlerhafter Anwendung von Dosieraerosolen. Pneumologie 1994; 48:191-196.
  24. van Beerendonk I, Mesters I, Mudde AN, Tan TD. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998; 35:273-279.
  25. McFadden ER, Jr. Improper patient techniques with metered dose inhalers: clinical consequences and solutions to misuse. J Allergy Clin Immunol 1995; 96:278-283.
  26. Hanania NA, Wittman R, Kesten S, Chapman KR. Medical personnel's knowledge of and ability to use inhaling devices. Metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers. Chest 1994; 105:111-116.
  27. Kesten S, Zive K, Chapman KR. Pharmacist knowledge and ability to use inhaled medication delivery systems. Chest 1993; 104:1737-1742.
  28. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med 1994; 154:1349-1352.
  29. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen LM. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. J Asthma 2003; 40:93-101.
  30. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150:1881-1884.
  31. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL. How often is medication taken as prescribed? A novel assessment technique. Jama 1989; 261:3273-3277.
  32. Coutts JA, Gibson NA, Paton JY. Measuring compliance with inhaled medication in asthma. Arch Dis Child 1992; 67:332-333.
  33. Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994; 7:504-509.
  34. Stoloff SW, Stempel DA, Meyer J, Stanford RH, Carranza Rosenzweig JR. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004; 113:245-251.
  35. Wasserfallen JB, Baraniuk JN. Clinical use of inhaled corticosteroids in asthma. J Allergy Clin Immunol 1996; 97:177-182.
  36. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996; 98:1051-1057.
  37. Bender B, Milgrom H, Rand C, Ackerson L. Psychological factors associated with medication nonadherence in asthmatic children. J Asthma 1998; 35:347-353.
  38. Cochrane GM, Horne R, Chanez P. Compliance in asthma. Respir Med 1999; 93:763-769.
  39. Rubin BK. What does it mean when a patient says, "my asthma medication is not working?" Chest 2004; 126:972-981.
  40. Lewis RM, Fink JB. Promoting adherence to inhaled therapy: building partnerships through patient education. Respir Care Clin N Am 2001; 7:277-301, vi.